Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

RNN $0.73 0.0680 +10.27%
IMNP $3.79 0.2900 +8.29%
MRTX $18.07 1.3200 +7.88%
CBMG $18.40 1.2850 +7.51%
MGNX $20.15 1.3000 +6.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TGTX $8.26 -1.3350 -13.92%
VRML $2.37 -0.1300 -5.20%
GERN $2.59 -0.1300 -4.78%
CNDO $1.64 -0.0600 -3.53%
CTIC $2.66 -0.0800 -2.92%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

Should Age Limits be Placed on Pricey Cancer Medicines? A Reader Poll

(Wall Street Journal/Pharmalot blog) July 2, 2014 - As governments, insurers and patients grapple with the rising cost of prescription medicines, the idea of rationing is increasingly discussed. The concept is antithetical in the U.S., but is part of the debate elsewhere over the value derived from pricey treatments that may strain budgets.
read article (paid subscription required) 

Japanese Stem-Cell 'Breakthrough' Findings Retracted

(BBC News) July 2, 2014 - Scientists in Japan had claimed stem cells could be made cheaply, quickly and ethically just by dipping blood cells into acid. They have now written a retraction that apologises for "multiple errors" in their report.
read article 

Marrow Transplants Can Reverse Adult Sickle Cell

( Press) July 2, 2014 - Bone marrow transplants can reverse severe sickle cell disease in adults, a small study by government scientists found, echoing results seen with a similar technique used in children.
read article 

NIH Names New Clinical Sites in Undiagnosed Diseases Network

(NIH) July 1, 2014 - The National Institutes of Health has awarded grants to six medical centers around the country to select from the most difficult-to-solve medical cases and together develop effective approaches to diagnose them.
read press release  

Bristol-Myers Recalls Six Lots of Blood Thinner Injection

(Reuters) July 1, 2014 - Bristol-Myers Squibb Co said it was voluntarily recalling six lots of the injectable version of its blood thinner, Coumadin, in the United States, after particulate matter was found in some unreleased samples.
read article 

France to Back Roche Cancer Drug as Cheaper Eye Treatment

(Reuters) July 2, 2014 - The French government, looking to cut healthcare costs, plans to authorise the use of Roche cancer drug Avastin as an alternative eye disease treatment to the much pricier Lucentis, marketed by both Roche and Novartis.
read article 

FDA Tightens Oversight of Pharmacies

(The Hill) July 1, 2014 - The Food and Drug Administration is beefing up its oversight of pharmacies that create custom drugs in response to a 2012 meningitis outbreak linked to tainted medicines that left 64 people dead.
read article 

CeGaT Selects N-of-One to Provide Clinical Interpretation for Next-Generation Sequencing Tests

(Yahoo! Finance) July 1, 2014 - CeGaT, a leading, innovative laboratory that provides a wide array of molecular diagnostics tests, has announced an agreement with N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology.
read article 

MDxHealth and Miraca Life Sciences Announce Agreement to Promote ConfirmMDx for Prostate Cancer

(MDxHealth) July 2, 2014 - MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into an agreement with Miraca Life Sciences (MLS), the nation's largest independent anatomic pathology lab, to promote MDxHealth's ConfirmMDx® for Prostate Cancer test.
read corporate press release 

Boston Strategics Licenses Phase 2-Ready Oncology Drug From Japan’s Eisai

(MedCity News) July 2, 2014 - Boston Strategics, a United States-based drug research and development company, has signed a license and development agreement with Eisai, a Japan-based global pharmaceutical company, it was reported yesterday.
read article 

Bluebird Bio in Deal to Buy Seattle Biotech For Up to $156M

(Boston Business Journal/Bioflash blog) July 1, 2014 - Cambridge biotech bluebird bio has acquired Precision Genome Engineering Inc., a Seattle-based biotech, in a cash and stock deal valued at up to $156 million.
read article 

CancerCare® Board of Trustees Appoints New President, Michael Parisi

(CancerCare/CopeLink blog) July 1, 2014 – CancerCare, the leading national nonprofit organization providing free, professional support services and financial assistance to anyone affected by cancer, is pleased to announce the appointment of Michael Parisi as President of its Board of Trustees.
read article 

Roswell Park Cancer Institute Receives “Outstanding” Distinction, as Recognized by the National Cancer Institute’s Comprehensive Cancer Center Status

(RPCI) July 1, 2014 - The National Cancer Institute (NCI) has renewed the coveted and prestigious Cancer Center Support Grant (CCSG) to Roswell Park Cancer Institute (RPCI) following an in-depth peer review by cancer experts from around the United States.
read press release 

Dana-Farber Acquires Commonwealth Hematology-Oncology

(Dana-Farber) July 1, 2014 - Dana-Farber Cancer Institute is acquiring the Commonwealth Hematology-Oncology (CHO) physician practice and extending its sophisticated cancer care model further into the community, effective July 1, 2014.
read press release 

NCI Approves Funding Plan for NCI Community Oncology Research Program (NCORP)

(NCI DCP) June 25, 2014 - On June 24, 2014, the Scientific Program Leaders (SPL) of the National Cancer Institute (NCI) approved the funding plan for the NCI Community Oncology Research Program (NCORP), a national network of investigators, cancer care providers, academic institutions, and other organizations.
read article 

New Program to Detect Early Lung Cancer in Current and Former Smokers

(New York Presbyterian) July 2, 2014 - In response to a recent national study showing that CT scans in a select high-risk population lower lung cancer deaths, NewYork-Presbyterian/Weill Cornell Medical Center has launched a lung cancer screening program for those at risk for developing the disease.
read press release 

Lung Cancer Alliance Commends National Cancer Institute For Its New Scientific Framework For Small Cell Lung Cancer

(Lung Cancer Alliance) July 1, 2014 - Today the National Cancer Institute (NCI), led by Harold Varmus, MD, presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer, one of the most lethal forms of the disease.
read press release 

Medicare-Backed Breast Cancer Screenings Skyrocket, But Do Patients Benefit?

(Yale News) July 1, 2014 - Breast cancer screening costs for Medicare patients skyrocketed between 2001 and 2009, but the increase did not lead to earlier detection of new breast cancer cases, according to a study published by Yale School of Medicine researchers in the July 1 Journal of the National Cancer Institute.
read article 

Deep Frozen Testicle Tissue Used to Produce Babies in Mice

(Reuters) July 1, 2014 - Scientists have for the first time produced live offspring from testicle tissue that has been cryopreserved, or deep frozen, and say a similar technique might one day be used to preserve the fertility of boys facing cancer treatment.
read article 

Biomarker Predicts Effectiveness of Brain Cancer Treatment

(UC San Diego Health System) July 1, 2014 - Researchers at the University of California, San Diego School of Medicine have identified a new biomarker that predicts whether glioblastoma – the most common form of primary brain cancer – will respond to chemotherapy. The findings are published in the July print issue of Oncotarget.
read press release 

Hypervigilance Critical For Difficult-to-Detect Melanoma

(Doctors Lounge/HealthDay News) July 1, 2014 — Monitoring patients at extreme risk with total-body photography (TBP) and sequential digital dermoscopy imaging (SDDI) assists with early diagnosis of primary melanoma, according to a study published online June 25 in JAMA Dermatology.
read article 

Single-Dose Breast Cancer Treatment Offers New Hope for Early-Stage Breast Cancer Patients

(Rush University Medical Center) July 1, 2014 - Women with early-stage breast cancer may now receive a one-dose radiation treatment at the same time as lumpectomy surgery, eliminating the need to return to the hospital daily for up to six weeks for post surgical radiation treatments.
read press release 

Mayo Clinic Recommends New Routine Testing for Some Non-Hodgkin Lymphomas

(Mayo Clinic) June 26, 2014 - A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL).
read press release 

Scientists Engineer Nanoparticles to Prevent Bone Cancer, Strengthen Bones

(Dana-Farber) June 30, 2014 - A research collaboration between Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH) has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent bone cancer progression.
read press release 

Proton Therapy Has Advantages Over IMRT For Advanced Head and Neck Cancers, Mayo Study Finds

(Mayo Clinic) July 1, 2014 - A new study by radiation oncologists at Mayo Clinic comparing the world's literature on outcomes of proton beam therapy in the treatment of a variety of advanced head and neck cancers of the skull base compared to intensity modulated radiation therapy (IMRT) has found that proton beam therapy significantly improved disease free survival and tumor control when compared to IMRT. The results appear in the journal Lancet Oncology.
read press release